Table 5.

Current studies on the efficacy of EGFR inhibitors in lung cancer.

Inhibitor	NCT number	Phase	Population	Treatment	Estimated enrollment	Primary outcome	Status
Afatinib	NCT03727724 (AFACET)	II	Advanced/metastatic NSCLC with EGFRex20ins	Afatinib 40 mg QD, cetuximab 500 mg/m2 iv Q2W	37	DCR	Recruiting
	NCT04206787(START)	NA	Advanced/metastatic NSCLC with EGFRm	Afatinib and 3rd generation EGFR TKI	825	TOT	Recruiting
	NCT03810872	II	Advanced/metastatic cancers harboring either an activating EGFR mutation or a HER2 mutation or a HER3 mutation	Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2	87	ORR and Incidence and intensity of adverse events	Recruiting
Osimertinib	NCT03414814 (KCSG LU17-19)	II	Pretreated advanced/metastatic NSCLC with EGFRex20ins	Osimertinib 80 mg QD	28	ORR	Active, not recruiting
	NCT02496663	I	Previously treated NSCLC with EGFR mutation including EGFRex20ins	Osimertinib 80 mg QD Necitumumab	100	Safety and tolerability	Recruiting
	NCT02151981	III	Locally advanced or metastatic NSCLC with T790M mutation	Osimertinib 80 mg QD	419	PFS	Recruiting
	NCT04035486(FLAURA2)	III	Advanced/metastatic NSCLC with EGFR mutation	Osimertinib 80mg QD	586	PFS	Recruiting
	NCT03460275	II	Advanced/metastatic NSCLC with EGFR mutation	Osimertinib Mesylate Tablets 80 mg QD	100	RECIST	Recruiting
	NCT03219970	NA	Locally advanced or metastatic NSCLC with T790M mutation	Osimertinib 80mg QD	156	OS	Active, not recruiting
	NCT03521154(LAURA)	III	Previously treated NSCLC with EGFR mutation	Osimertinib 80mg/40mg	200	PFS	Recruiting
	NCT02442349(AURA17)	II	Previously treated NSCLC with EGFR mutation	Osimertinib 80mg QD	171	ORR	Recruiting
Avitinib	NCT03856697	III	Advanced/metastatic NSCLC with EGFR mutation	Avitinib Maleate Capsules 300mg BID	406	PFS	Not yet recruiting
	NCT02274337	I/II	Previously treated advanced/metastatic NSCLC with EGFR mutation	Avitinib QD different dose stage	100	Safety, tolerability and ORR	Not yet recruiting
Olmutinib (HM61713)	NCT02485652	II	Previously treated NSCLC with EGFR T790M mutation	HM61713 800 mg QD	162	ORR	Active, not recruiting
Poziotinib	NCT04044170	II	Previously treated NSCLC with EGFRex20ins or HER2 ex20ins	Poziotinib orally	114	ORR	Active, not recruiting
Mobocertinib (TAK-788)	NCT03807778	I/II	Previously treated NSCLC with EGFRex20ins	TAK-788 40mg QD phase 1, TAK-788 160 mg QD phase 2	63	ORR	Recruiting
Pyrotinib	NCT04063462	II	Previously treated NSCLC with EGFRex20ins or HER2 ex20ins	Pyrotinib 400 mg QD	60	ORR	Not yet recruiting
	NCT03574402 (TRUMP)	II	Arm9: NSCLC with EGFRex20ins	Pyrotinib either 60 mg QD or 40 mg BID	400	ORR	Recruiting
Tarloxotinib (TH-4000)	NCT03805841 (RAIN)	II	NSCLC with EGFR ex20ins or HER2 activating mutation	Tarloxotinib bromide	60	ORR	Recruiting
DZD9008	NCT03974022	I/II	Advanced/metastatic NSCLC with EGFR/HER2 mutations	DZD9008	160	ORR	Recruiting
Lazertinib (YH25448)	NCT04248829 (Lazertinib)	III	Locally advanced or metastatic NSCLC with EGFR mutation	Lazertinib 240 mg/160 mg	380	PFS	Recruiting
JNJ-61186372	NCT04077463	I/II	Previously treated NSCLC with EGFR mutation	Lazertinib and JNJ-61186372	120	DLT and ORR	Recruiting
	NCT02609776	I	Previously treated NSCLC with EGFR mutation	JNJ-61186372 140 mg	460	DLT and ORR	Recruiting

NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; Ex, exon; Ins, insertion; HER2, human epidermal growth factor receptor2; Mut, mutation; QD, once daily; BID, twice daily; DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression free survival; RECIST, response evaluation criteria in solid tumors; TOT, time on treatment; DLT, dose limiting toxicity. NA, missing value.